Artiva Biotherapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
ARTV$4.06-3.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| NINE MONTHS ENDED SEPTEMBER 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities: | ||
| Net loss | $(49,278) | $(16,722) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Depreciation and amortization | 1,817 | 1,672 |
| Stock-based compensation | 4,796 | 5,661 |
| Change in fair value of SAFEs (including related party amounts of $2,911 and $0, respectively) | 3,597 | — |
| Accretion of discounts and amortization of premiums on investments, net | (1,300) | (173) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 465 | (1,612) |
| Other receivables (including related party amounts of $(593) and $(1,040), respectively) | 592 | (1,338) |
| Prepaid expenses and other current assets | (2,141) | 298 |
| Other long-term assets | 94 | 94 |
| Accounts payable (including related party amounts of $104 and $678, respectively) | 601 | 1,514 |
| Accrued expenses (including related party amounts of $(854) and $345, respectively) | 333 | (1,055) |
| Operating lease right-of-use asset and lease liabilities | 42 | 117 |
| Deferred revenue | — | (25,211) |
| Net cash used in operating activities | (40,382) | (36,755) |
| Investing activities: | ||
| Purchases of property and equipment | (578) | (2,622) |
| Purchases of investments | (161,319) | (34,685) |
| Maturities of investments | 42,400 | 14,000 |
| Net cash used in investing activities | (119,497) | (23,307) |
| Financing activities: | ||
| Proceeds from issuance of common stock, net of commissions | 166,507 | — |
| Proceeds from issuance of simple agreements for future equity | — | 23,431 |
| Proceeds from exercise of stock options | 28 | 10 |
| Payments on finance leases | (116) | — |
| Cash paid in connection with IPO offering costs | (4,163) | — |
| Repurchase of restricted stock | — | (12) |
| Net cash provided by financing activities | 162,256 | 23,429 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 2,377 | (36,633) |
| Cash, cash equivalents and restricted cash at beginning of period | 53,762 | 102,776 |
| Cash, cash equivalents and restricted cash at end of period | $56,139 | $66,143 |
| Reconciliation of cash, cash equivalents and restricted cash to the balance sheet: | ||
| Cash and cash equivalents | $55,881 | $65,885 |
| Restricted cash | 258 | 258 |
| Total cash, cash equivalents and restricted cash | $56,139 | $66,143 |
| Supplemental disclosures of noncash activities: | ||
| Property and equipment purchases in accounts payable and accrued liabilities | $10 | $617 |
| Deferred offering costs in accounts payable and accrued liabilities | $19 | $— |
| Conversion of SAFE notes to common stock | $28,697 | $— |
| Conversion of preferred stock to common stock | $216,413 | $— |
| Non-cash additions to financing leases | $241 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.